INOVIO PHARMACEUTICALS INC's ticker is INO and the CUSIP is 45773H201. A total of 121 filers reported holding INOVIO PHARMACEUTICALS INC in Q3 2019. The put-call ratio across all filers is 0.78 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $370,000 | -28.0% | 103,038 | 0.0% | 0.13% | -21.8% |
| Q4 2021 | $514,000 | -42.1% | 103,038 | -17.9% | 0.16% | -42.7% |
| Q3 2021 | $887,000 | -29.3% | 125,466 | -7.4% | 0.29% | -30.9% |
| Q2 2021 | $1,255,000 | +3.7% | 135,466 | +3.8% | 0.42% | -3.5% |
| Q1 2021 | $1,210,000 | +37.3% | 130,466 | +31.1% | 0.43% | +12.8% |
| Q4 2020 | $881,000 | -36.7% | 99,496 | -17.0% | 0.38% | -44.1% |
| Q3 2020 | $1,391,000 | +28.3% | 119,914 | +197.9% | 0.68% | +7.0% |
| Q2 2020 | $1,084,000 | -36.2% | 40,251 | -82.4% | 0.64% | -48.4% |
| Q1 2020 | $1,698,000 | -9.9% | 228,260 | -60.0% | 1.24% | -25.9% |
| Q4 2019 | $1,884,000 | +47.3% | 570,800 | -8.3% | 1.67% | +47.4% |
| Q3 2019 | $1,279,000 | -33.4% | 622,300 | -4.1% | 1.14% | -26.9% |
| Q2 2019 | $1,920,000 | -60.6% | 648,800 | -49.1% | 1.55% | -26.7% |
| Q1 2019 | $4,877,000 | +109.9% | 1,273,500 | +119.2% | 2.12% | -4.2% |
| Q4 2018 | $2,324,000 | – | 581,100 | – | 2.21% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Defender Capital, LLC. | 648,800 | $1,920,000 | 1.55% |
| Round Table Services, LLC | 339,391 | $998,000 | 0.31% |
| ARK Investment Management | 3,955,017 | $11,628,000 | 0.29% |
| Nikko Asset Management Americas, Inc. | 4,884,100 | $14,359,000 | 0.28% |
| WASATCH ADVISORS LP | 6,735,726 | $19,803,000 | 0.19% |
| Cedar Brook Financial Partners, LLC | 41,500 | $122,000 | 0.06% |
| Unified Trust Company, N.A. | 15,716 | $46,000 | 0.03% |
| Bay Colony Advisory Group, Inc d/b/a Bay Colony Advisors | 13,500 | $40,000 | 0.03% |
| STONERIDGE INVESTMENT PARTNERS LLC | 16,914 | $50,000 | 0.02% |
| Sumitomo Mitsui Trust Holdings, Inc. | 4,884,100 | $14,359,000 | 0.01% |